iVascular®
therapies for living

iVolution pro

Self-expanding peripheral stent system

Quality as first option



New delivery system

EV

www.ivascular.global

New delive

Simple and controlled stent deployment

No jumping effect

Optimum visibility

- 2 markers delimiting the stent
- 1 tungsten marker in the retractable sheath indicating the implantation level



Triple sheath design

to control deployment forces and facilitate precise placement



*iVascular internal data

ery system

Controlled deployment

The deployment speed can be modulated with the wheel



Ergonomic and small handle

10cm shorter than main competitors*

Stent quality

Quality assured to avoid stent fracture

100% of stents checked

No reported stent fractures in the EVOLUTION trial at 1-year[1]

Best corrosion resistance and **lowest inclusion fraction** reported[2]



Inclusions are small particles inside the nitinol matrix. They are known as a fatigue starting points

Highest elastic recovery & **minimum brittleness**

Hydrogen in stent can suppress elastic recovery and promote brittleness. iVolution pro is the stent with lowest hydrogen content[3]



[1] M Bosiers et al. EVOLUTION Study: 12-month results. 2019 Aug;60(4):490-495.
[2] F Sun et al. On the High Sensitivity of Corrosion Resistance of NiTi Stents with Respect to Inclusions: An Experimental Evidence, ACS Omega, 2020
[3] F Sun et al. Revisiting the effects of low-concentration hydrogen in NiTi self-expandable stents. Materials Science & Engineering C 118 (2021) 111405

Stent design



Resistance

Stress homogeneously distributed to avoid stent fracture

Flexibility

Open cell design to offer the highest flexibility

Visibility

4 tantalum markers at each end



No flaking

Avoids vessel wall damage



No jumping effect

Closed cell design ends for deployment stability

Anti-kinking

Maintains inner lumen

Clinical e

Highest efficacy outcomes

EVOLUTION Trial[1]

- Physician-initiated, prospective, and multicentric trial, investigating the efficacy of iVolution
- PI: Dr Marc Bosiers
- N:120 patients
- Symptomatic (Rutherford 2-4) femoropopliteal arterial stenotic or occlusive lesions.
- Follow-up: 1 year

PP
86.3%

fTLR
88.0%

Primary patency comparison



evidence

in femoropopliteal arteries

TINTIN Trial (1-year follow-up)[2]

- Physician initiated, prospective, multi-center trial, investigating the safety and efficacy of the treatment with Luminor and iVolution
- PI: Dr Koen Deloose
- N: 100 patients
- TASC C and D femoropopliteal atherosclerotic lesions
- Follow-up: 1, 2, 3, 4 and 5 years

Main lesion length
24.3cm

fTLR
94.4%

PP
90.5%

Comparison of main lesion length vs PP at 1-year follow up between 26 trials



[1] M Bosiers et al. EVOLUTION Study: 12-month results. 2019 Aug;60(4):490-495. [2] K Deloose. LINC 2020 presentation

iVolution pro
features

- **Triple sheath** catheter
- Catheter length: **80** and **130** cm
- Introducer compatibility: **6F**
- Guiding catheter compatibility: **8F**
- Portfolio:
  - Ø: 5-10mm
  - Length: 40-200mm
- Guidewire compatibility: **0.035”**



Product with CE mark, certified by Notified Body 0318

Usable catheter length (cm)	Stent Diameter (mm)	Stent length (mm)					
		40	60	80	100	150	200
80	5	SPNBC35N080050040	SPNBC35N080050060	SPNBC35N080050080	SPNBC35N080050100	SPNBC35N080050150	SPNBC35N080050200
	6	SPNBC35N080060040	SPNBC35N080060060	SPNBC35N080060080	SPNBC35N080060100	SPNBC35N080060150	SPNBC35N080060200
	7	SPNBC35N080070040	SPNBC35N080070060	SPNBC35N080070080	SPNBC35N080070100	SPNBC35N080070150	SPNBC35N080070200
	8	SPNBC35N080080040	SPNBC35N080080060	SPNBC35N080080080	SPNBC35N080080100	SPNBC35N080080150	-
	9	SPNBC35N080090040	SPNBC35N080090060	SPNBC35N080090080	SPNBC35N080090100	-	-
	10	SPNBC35N080100040	SPNBC35N080100060	SPNBC35N080100080	SPNBC35N080100100	-	-
130	5	SPNBC35N130050040	SPNBC35N130050060	SPNBC35N130050080	SPNBC35N130050100	SPNBC35N130050150	SPNBC35N130050200
	6	SPNBC35N130060040	SPNBC35N130060060	SPNBC35N130060080	SPNBC35N130060100	SPNBC35N130060150	SPNBC35N130060200
	7	SPNBC35N130070040	SPNBC35N130070060	SPNBC35N130070080	SPNBC35N130070100	SPNBC35N130070150	SPNBC35N130070200
	8	SPNBC35N130080040	SPNBC35N130080060	SPNBC35N130080080	SPNBC35N130080100	SPNBC35N130080150	-
	9	SPNBC35N130090040	SPNBC35N130090060	SPNBC35N130090080	SPNBC35N130090100	-	-
	10	SPNBC35N130100040	SPNBC35N130100060	SPNBC35N130100080	SPNBC35N130100100	-	-

The availability of each reference for the sale is linked to the authorization of commercialization in the country of destination

Introducer compatibility: **6F**

Distributed by:

INTEGRATED MANUFACTURER

Manufactured by:

Life Vascular Devices Biotech S.L
www.ivascular.global
info@ivascular.global

MP51261 Ed.0 Oct 2020